Skip to main content
Premium Trial:

Request an Annual Quote

Biodesix Raises $12M in Series D Extension

NEW YORK (GenomeWeb News) – Biodesix today announced the closing of a $12 million extension of its Series D financing round.

The funds will support commercialization of its VeriStrat blood-based test for non-small cell lung cancer, as well as clinical validation studies, product development, and ongoing collaborations with biotechnology and pharmaceutical companies.

The Boulder-based molecular diagnostic firm closed on the Series D round in July 2011, raising $20 million. Biodesix said it plans to pursue clearance from the US Food and Drug Administration for VeriStrat, a mass spectrometry-based test performed out of the company's CLIA laboratory to help guide physicians treating patients with NSCLC.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.